Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms

Provided herein are methods for reducing neoplastic progenitor cell proliferation and alleviating symptoms associated in individuals diagnosed with or thought to have myeloproliferative disorders, such as Essential Thrombocythemia (ET). Also provided herein are methods for using telomerase inhibitor...

Full description

Saved in:
Bibliographic Details
Main Authors Stuart, Monic J, Kelsey, Stephen
Format Patent
LanguageEnglish
Published 08.08.2024
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Provided herein are methods for reducing neoplastic progenitor cell proliferation and alleviating symptoms associated in individuals diagnosed with or thought to have myeloproliferative disorders, such as Essential Thrombocythemia (ET). Also provided herein are methods for using telomerase inhibitors for maintaining blood platelet counts at relatively normal ranges in the blood of individuals diagnosed with or suspected of having myeloproliferative disorder s, such as ET. WO 20141088785 PCT/US2013/070437 Figure 140.00 --- 140.00- 840.00 - - - - - - - - - - - - - - - - - - --- 00.00 x "Fu 40.00 --- 20.00 - Day Day Day Day Day Day Day Day Day Day Day 0 1 2 3 4 5 6 7 10 14 17 Imetelstat 0.9 uM 422.001837855 * Imetelstat 1.875 uM200 2.7 3.22 00 74421.5630.755550 11504573970 SImetelstat 3.75 uM 2.00 1.56 2.56 5.00 8.11 16.44 2700383310103975600 E Imetelstat 7.5 uM 2.00 1.44 2.00 4.56,10.44 15.4426.7541.00196.50 46.33 52.30 E lmetelstat 15 uM 2.00 1.89 3.00 4.78 7.56 15.5625.20 3933107.5 36.3335.70 z Standard Control 2.00 2.00 2.44 4.33 9.22 15.3325.33 56001141.0 18.83 38.70 5olvent Control '2.0042563.33 4.57 11.22''53,124.317O2.~3,0
Bibliography:Application Number: AU20200267142